0001209191-20-025987.txt : 20200428
0001209191-20-025987.hdr.sgml : 20200428
20200428171058
ACCESSION NUMBER: 0001209191-20-025987
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200428
FILED AS OF DATE: 20200428
DATE AS OF CHANGE: 20200428
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Svennilson Peter
CENTRAL INDEX KEY: 0001606074
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39269
FILM NUMBER: 20826080
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oric Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001796280
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 471787157
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 240 E. GRAND AVE.
STREET 2: 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 388-5600
MAIL ADDRESS:
STREET 1: 240 E. GRAND AVE.
STREET 2: 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-04-28
0
0001796280
Oric Pharmaceuticals, Inc.
ORIC
0001606074
Svennilson Peter
1700 OWENS STREET, SUITE 500
SAN FRANCISCO
CA
94158
1
0
1
0
Common Stock
2020-04-28
4
C
0
3500000
A
3575000
I
See footnote
Common Stock
2020-04-28
4
C
0
625000
A
4200000
I
See footnote
Common Stock
2020-04-28
4
C
0
416666
A
4616666
I
See footnote
Common Stock
2020-04-28
4
C
0
151515
A
4768181
I
See footnote
Series A Preferred Stock
2020-04-28
4
C
0
3500000
0.00
D
Common Stock
3500000
0
I
See footnote
Series B Preferred Stock
2020-04-28
4
C
0
625000
0.00
D
Common Stock
625000
0
I
See footnote
Series C Preferred Stock
2020-04-28
4
C
0
416666
0.00
D
Common Stock
416666
0
I
See footnote
Series D Preferred Stock
2020-04-28
4
C
0
151515
0.00
D
Common Stock
151515
0
I
See footnote
Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.
The shares are held of record by The Column Group II, LP ("TCG II LP"). The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP. The Reporting Person is a Managing Partner of TCG II GP and may be deemed to share voting and investment power with respect to the shares reported herein. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any.
/s/ Dominic Piscitelli, attorney-in-fact
2020-04-28